Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

OBJECTIVE: In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA(1c)) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This post hoc analysis investigated the impact of clinically relevant subject characteristics o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Pratley, Richard E, Aroda, Vanita R, Catarig, Andrei-Mircea, Lingvay, Ildiko, Lüdemann, Jörg, Yildirim, Emre, Viljoen, Adie
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Diabetes and Endocrinology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670946/
https://ncbi.nlm.nih.gov/pubmed/33199417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-037883
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars